Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.45
(2.46%)
USD 0.45
(2.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 136.31 Million USD | 76.64% |
| 2022 | 77.17 Million USD | 231.02% |
| 2021 | 23.31 Million USD | -50.83% |
| 2020 | 47.41 Million USD | -84.23% |
| 2019 | 300.61 Million USD | -3.2% |
| 2018 | 310.54 Million USD | -19.22% |
| 2017 | 384.43 Million USD | 20.81% |
| 2016 | 318.22 Million USD | -13.76% |
| 2015 | 368.98 Million USD | 96.94% |
| 2014 | 187.35 Million USD | 80.16% |
| 2013 | 103.99 Million USD | -1.05% |
| 2012 | 105.1 Million USD | -20.94% |
| 2011 | 132.94 Million USD | 10.92% |
| 2010 | 119.86 Million USD | 27.15% |
| 2009 | 94.26 Million USD | 43.52% |
| 2008 | 65.68 Million USD | -20.6% |
| 2007 | 82.72 Million USD | -21.04% |
| 2006 | 104.76 Million USD | -21.18% |
| 2005 | 132.91 Million USD | 47.05% |
| 2004 | 90.38 Million USD | -23.39% |
| 2003 | 117.98 Million USD | 270.2% |
| 2002 | 31.87 Million USD | 47.42% |
| 2001 | 21.61 Million USD | 65.47% |
| 2000 | 13.06 Million USD | -7.34% |
| 1999 | 14.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 133.37 Million USD | 3.91% |
| 2024 Q1 | 128.35 Million USD | -5.84% |
| 2023 FY | 136.31 Million USD | 76.64% |
| 2023 Q4 | 136.31 Million USD | -0.47% |
| 2023 Q1 | 74.67 Million USD | -3.25% |
| 2023 Q3 | 136.96 Million USD | 5.07% |
| 2023 Q2 | 130.36 Million USD | 74.59% |
| 2022 Q3 | 47.66 Million USD | 14.87% |
| 2022 Q2 | 41.49 Million USD | -4.57% |
| 2022 Q1 | 43.48 Million USD | 86.5% |
| 2022 FY | 77.17 Million USD | 231.02% |
| 2022 Q4 | 77.17 Million USD | 61.9% |
| 2021 FY | 23.31 Million USD | -50.83% |
| 2021 Q3 | 35.72 Million USD | 3.74% |
| 2021 Q4 | 23.31 Million USD | -34.74% |
| 2021 Q1 | 40.71 Million USD | -14.14% |
| 2021 Q2 | 34.43 Million USD | -15.41% |
| 2020 Q3 | 91.28 Million USD | -72.6% |
| 2020 Q2 | 333.22 Million USD | 5.52% |
| 2020 Q1 | 315.79 Million USD | 5.05% |
| 2020 FY | 47.41 Million USD | -84.23% |
| 2020 Q4 | 47.41 Million USD | -48.06% |
| 2019 Q4 | 300.61 Million USD | 7.41% |
| 2019 FY | 300.61 Million USD | -3.2% |
| 2019 Q2 | 298.02 Million USD | -2.03% |
| 2019 Q1 | 304.2 Million USD | -2.04% |
| 2019 Q3 | 279.87 Million USD | -6.09% |
| 2018 Q2 | 338 Million USD | -6.27% |
| 2018 FY | 310.54 Million USD | -19.22% |
| 2018 Q4 | 310.54 Million USD | -8.55% |
| 2018 Q1 | 360.61 Million USD | -6.2% |
| 2018 Q3 | 339.59 Million USD | 0.47% |
| 2017 Q2 | 257.2 Million USD | -1.7% |
| 2017 Q4 | 384.43 Million USD | 53.09% |
| 2017 FY | 384.43 Million USD | 20.81% |
| 2017 Q1 | 261.66 Million USD | -17.77% |
| 2017 Q3 | 251.11 Million USD | -2.37% |
| 2016 Q3 | 331.76 Million USD | -2.65% |
| 2016 FY | 318.22 Million USD | -13.76% |
| 2016 Q4 | 318.22 Million USD | -4.08% |
| 2016 Q1 | 358.46 Million USD | -2.85% |
| 2016 Q2 | 340.8 Million USD | -4.93% |
| 2015 Q2 | 184.49 Million USD | -1.38% |
| 2015 FY | 368.98 Million USD | 96.94% |
| 2015 Q3 | 193.2 Million USD | 4.72% |
| 2015 Q1 | 187.07 Million USD | -0.15% |
| 2015 Q4 | 368.98 Million USD | 90.98% |
| 2014 Q4 | 187.35 Million USD | 70.79% |
| 2014 FY | 187.35 Million USD | 80.16% |
| 2014 Q2 | 107.39 Million USD | 4.45% |
| 2014 Q3 | 109.69 Million USD | 2.14% |
| 2014 Q1 | 102.82 Million USD | -1.13% |
| 2013 Q4 | 103.99 Million USD | -8.57% |
| 2013 FY | 103.99 Million USD | -1.05% |
| 2013 Q3 | 113.74 Million USD | 5.02% |
| 2013 Q2 | 108.3 Million USD | 3.09% |
| 2013 Q1 | 105.06 Million USD | -0.03% |
| 2012 Q3 | 105.07 Million USD | -22.83% |
| 2012 Q4 | 105.1 Million USD | 0.02% |
| 2012 Q2 | 136.16 Million USD | 1.75% |
| 2012 Q1 | 133.82 Million USD | 0.66% |
| 2012 FY | 105.1 Million USD | -20.94% |
| 2011 Q1 | 124.09 Million USD | 3.53% |
| 2011 FY | 132.94 Million USD | 10.92% |
| 2011 Q4 | 132.94 Million USD | 6.16% |
| 2011 Q3 | 125.22 Million USD | 2.87% |
| 2011 Q2 | 121.72 Million USD | -1.9% |
| 2010 Q3 | 102.01 Million USD | 45.49% |
| 2010 Q4 | 119.86 Million USD | 17.49% |
| 2010 FY | 119.86 Million USD | 27.15% |
| 2010 Q1 | 90.3 Million USD | -4.2% |
| 2010 Q2 | 70.12 Million USD | -22.35% |
| 2009 Q4 | 94.26 Million USD | 0.51% |
| 2009 Q1 | 71.16 Million USD | 8.34% |
| 2009 Q2 | 93.22 Million USD | 31.0% |
| 2009 Q3 | 93.78 Million USD | 0.6% |
| 2009 FY | 94.26 Million USD | 43.52% |
| 2008 Q1 | 73.42 Million USD | -11.24% |
| 2008 FY | 65.68 Million USD | -20.6% |
| 2008 Q4 | 65.68 Million USD | -5.85% |
| 2008 Q3 | 69.76 Million USD | -3.98% |
| 2008 Q2 | 72.65 Million USD | -1.06% |
| 2007 Q1 | 98.36 Million USD | -6.11% |
| 2007 FY | 82.72 Million USD | -21.04% |
| 2007 Q4 | 82.72 Million USD | -4.72% |
| 2007 Q3 | 86.82 Million USD | -4.71% |
| 2007 Q2 | 91.11 Million USD | -7.37% |
| 2006 FY | 104.76 Million USD | -21.18% |
| 2006 Q2 | 120.81 Million USD | -4.39% |
| 2006 Q3 | 110.69 Million USD | -8.37% |
| 2006 Q4 | 104.76 Million USD | -5.36% |
| 2006 Q1 | 126.36 Million USD | -4.92% |
| 2005 FY | 132.91 Million USD | 47.05% |
| 2005 Q2 | 98.24 Million USD | 22.03% |
| 2005 Q3 | 129.11 Million USD | 31.42% |
| 2005 Q4 | 132.91 Million USD | 2.94% |
| 2005 Q1 | 80.5 Million USD | -10.93% |
| 2004 FY | 90.38 Million USD | -23.39% |
| 2004 Q4 | 90.38 Million USD | -2.96% |
| 2004 Q3 | 93.14 Million USD | 9.74% |
| 2004 Q2 | 84.87 Million USD | -22.95% |
| 2004 Q1 | 110.15 Million USD | -6.64% |
| 2003 Q2 | 33.07 Million USD | 24.12% |
| 2003 FY | 117.98 Million USD | 270.2% |
| 2003 Q1 | 26.64 Million USD | -16.39% |
| 2003 Q3 | 30.9 Million USD | -6.56% |
| 2003 Q4 | 117.98 Million USD | 281.81% |
| 2002 FY | 31.87 Million USD | 47.42% |
| 2002 Q4 | 31.87 Million USD | 78.18% |
| 2002 Q2 | 18.7 Million USD | -5.29% |
| 2002 Q3 | 17.88 Million USD | -4.39% |
| 2002 Q1 | 19.75 Million USD | -8.63% |
| 2001 Q2 | 26.44 Million USD | 114.12% |
| 2001 FY | 21.61 Million USD | 65.47% |
| 2001 Q3 | 22.72 Million USD | -14.08% |
| 2001 Q4 | 21.61 Million USD | -4.87% |
| 2001 Q1 | 12.35 Million USD | -5.45% |
| 2000 Q1 | 14.09 Million USD | 0.0% |
| 2000 Q3 | 8.91 Million USD | -25.52% |
| 2000 FY | 13.06 Million USD | -7.34% |
| 2000 Q2 | 11.97 Million USD | -15.04% |
| 2000 Q4 | 13.06 Million USD | 46.49% |
| 1999 FY | 14.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 59.402% |
| Alkermes plc | 933.53 Million USD | 85.398% |
| Agenus Inc. | 462.29 Million USD | 70.513% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.635% |
| Aptorum Group Limited | 5.25 Million USD | -2493.224% |
| Ardelyx, Inc. | 130.76 Million USD | -4.249% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 71.505% |
| Bicycle Therapeutics plc | 224.41 Million USD | 39.255% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -4.692% |
| ChromaDex Corporation | 26.5 Million USD | -414.256% |
| Chimerix, Inc. | 19.74 Million USD | -590.398% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -287.522% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -87.853% |
| CRISPR Therapeutics AG | 346.76 Million USD | 60.689% |
| Precision BioSciences, Inc. | 140.92 Million USD | 3.265% |
| Dyadic International, Inc. | 2.34 Million USD | -5723.978% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -738.216% |
| Fortress Biotech, Inc. | 165.93 Million USD | 17.85% |
| Lantern Pharma Inc. | 2.73 Million USD | -4875.723% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -90.709% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -3763.123% |
| Incyte Corporation | 1.59 Billion USD | 91.439% |
| IO Biotech, Inc. | 17.55 Million USD | -676.481% |
| Jaguar Health, Inc. | 45.86 Million USD | -197.211% |
| Novavax, Inc. | 2.57 Billion USD | 94.7% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -278.055% |
| Opthea Limited | 264.6 Million USD | 48.481% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -4.294% |
| ContextLogic Inc. | 206 Million USD | 33.826% |
| MiMedx Group, Inc. | 96.33 Million USD | -41.513% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -183.868% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -3762.946% |
| NextCure, Inc. | 14.99 Million USD | -808.975% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -3272.563% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -1941.62% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -191.66% |
| Vaxcyte, Inc. | 167.44 Million USD | 18.591% |
| PDS Biotechnology Corporation | 33.25 Million USD | -309.869% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 42.045% |
| Pharming Group N.V. | 244.07 Million USD | 44.148% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1043.424% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -6.673% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1963.164% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1963.164% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -65.369% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -1952.07% |
| Acelyrin, Inc. | 86.35 Million USD | -57.862% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -10392.203% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -848.042% |
| Summit Therapeutics Inc. | 125.25 Million USD | -8.831% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1338.116% |
| Senti Biosciences, Inc. | 52.57 Million USD | -159.305% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -98.204% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 10.028% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -6869.274% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -10106.849% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 39.903% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1355.311% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 40.065% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 72.433% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1149.029% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -395.507% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1026.166% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 71.985% |
| Immix Biopharma, Inc. | 3.72 Million USD | -3562.734% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -260.518% |
| MEI Pharma, Inc. | 8.35 Million USD | -1531.586% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -369.823% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 60.781% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 6.547% |
| Fortress Biotech, Inc. | 165.93 Million USD | 17.85% |
| Precigen, Inc. | 41.64 Million USD | -227.344% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -173.02% |
| AlloVir, Inc. | 45.01 Million USD | -202.83% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -4.59% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 1.075% |
| ImmuCell Corporation | 18.81 Million USD | -624.522% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -382.955% |
| Onconetix, Inc. | 23.18 Million USD | -488.066% |
| PureTech Health plc | 125.58 Million USD | -8.549% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1423.117% |
| Elevation Oncology, Inc. | 34.28 Million USD | -297.64% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -5475.419% |
| Seer, Inc. | 39.36 Million USD | -246.295% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -120.46% |
| Innoviva, Inc. | 568.55 Million USD | 76.023% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -400.657% |
| ESSA Pharma Inc. | 3.49 Million USD | -3800.321% |
| GlycoMimetics, Inc. | 6.9 Million USD | -1875.044% |
| GT Biopharma, Inc. | 6.63 Million USD | -1955.164% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 48.44% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 49.936% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -62.234% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1294.71% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -401.745% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -4125.933% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -84.797% |
| Aptose Biosciences Inc. | 15.8 Million USD | -762.304% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1134.809% |
| Soligenix, Inc. | 7.27 Million USD | -1773.825% |
| Century Therapeutics, Inc. | 175.94 Million USD | 22.52% |
| Kura Oncology, Inc. | 51.66 Million USD | -163.867% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -12.398% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -3198.306% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -1961.113% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 46.033% |
| Autolus Therapeutics plc | 263.9 Million USD | 48.346% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1200.506% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -53.407% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -190.665% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 61.367% |
| GRI Bio, Inc. | 2.69 Million USD | -4954.468% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -16738.133% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -338.452% |
| IGM Biosciences, Inc. | 220.17 Million USD | 38.087% |
| INmune Bio, Inc. | 18.86 Million USD | -622.718% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 46.85% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -411.673% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -4914.667% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -4055.73% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -133.203% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -41.764% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 48.507% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 83.437% |
| Verastem, Inc. | 71.18 Million USD | -91.5% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -177.206% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -253.359% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -178.589% |
| Histogen Inc. | 5.69 Million USD | -2292.821% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -3008.328% |
| Surrozen, Inc. | 8.14 Million USD | -1573.653% |
| Organovo Holdings, Inc. | 2.74 Million USD | -4860.662% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -43333.336% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -142.432% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -725.575% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -166.753% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -16386.047% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -7.571% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1160.627% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 9.656% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -5128.269% |
| Apollomics, Inc. | 14.15 Million USD | -863.181% |
| Amarin Corporation plc | 279.58 Million USD | 51.243% |
| Mesoblast Limited | 188.79 Million USD | 27.796% |
| Turnstone Biologics Corp. | 14.14 Million USD | -863.521% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 24.597% |
| Synaptogenix, Inc. | 5.52 Million USD | -2365.318% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -1950.526% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 19.863% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1493.034% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -7656.888% |
| Exelixis, Inc. | 678.44 Million USD | 79.907% |
| Better Therapeutics, Inc. | 23.84 Million USD | -471.76% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 16.902% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 77.059% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1176.371% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -8296.012% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -250.191% |
| Gritstone bio, Inc. | 125.91 Million USD | -8.259% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -828.857% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -2578.896% |
| Avid Bioservices, Inc. | 275.66 Million USD | 50.55% |
| Insmed Incorporated | 1.66 Billion USD | 91.797% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -1671.752% |
| MediWound Ltd. | 27.18 Million USD | -401.412% |
| OmniAb, Inc. | 87.4 Million USD | -55.971% |
| Alector, Inc. | 487.66 Million USD | 72.047% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 66.212% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -639.859% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -255.247% |
| Zai Lab Limited | 240.17 Million USD | 43.242% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 78.364% |
| Aura Biosciences, Inc. | 29.22 Million USD | -366.415% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -43.377% |
| Immunic, Inc. | 25.36 Million USD | -437.366% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -96.89% |
| Veracyte, Inc. | 93.71 Million USD | -45.455% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -5109.631% |
| FibroGen, Inc. | 585.72 Million USD | 76.727% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -684.209% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -20773.375% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2310.397% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.22% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1562.832% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -62.242% |
| TG Therapeutics, Inc. | 169.08 Million USD | 19.378% |
| Galecto, Inc. | 5.89 Million USD | -2212.059% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1545.57% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 94.794% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -372.969% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -980.097% |
| XBiotech Inc. | 8.39 Million USD | -1523.425% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -828.857% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -156.335% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 62.458% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -407.064% |
| Theravance Biopharma, Inc. | 169 Million USD | 19.34% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 88.786% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 72.759% |
| Vaxxinity, Inc. | 30.94 Million USD | -340.535% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 85.982% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2160.265% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 81.708% |
| NexImmune, Inc. | 5.08 Million USD | -2581.211% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -36604.686% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -4333.357% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.082% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -2544.901% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1728.697% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -418.441% |
| Ainos, Inc. | 7.39 Million USD | -1743.588% |
| Pluri Inc. | 34.11 Million USD | -299.622% |
| Prothena Corporation plc | 135.01 Million USD | -0.964% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 43.925% |
| Celularity Inc. | 102.92 Million USD | -32.44% |
| Rallybio Corporation | 9.43 Million USD | -1344.669% |
| Cue Biopharma, Inc. | 24.44 Million USD | -457.656% |
| MeiraGTx Holdings plc | 319.99 Million USD | 57.399% |
| Omeros Corporation | 403.25 Million USD | 66.195% |
| Humacyte, Inc. | 114.67 Million USD | -18.872% |
| Immunocore Holdings plc | 228.15 Million USD | 40.252% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -2696.287% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -77.637% |
| Blueprint Medicines Corporation | 918.64 Million USD | 85.161% |
| CalciMedica, Inc. | 4.02 Million USD | -3284.285% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -681.108% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 11.563% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -58.848% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 50.928% |
| Pulmatrix, Inc. | 15.96 Million USD | -753.969% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -764.255% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -454.007% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 45.648% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -168.418% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 88.74% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -328.905% |
| Nutriband Inc. | 1.07 Million USD | -12534.776% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1182.037% |
| Vor Biopharma Inc. | 59.1 Million USD | -130.643% |
| Roivant Sciences Ltd. | 773.95 Million USD | 82.387% |
| Evogene Ltd. | 17.99 Million USD | -657.749% |
| ProKidney Corp. | 29.21 Million USD | -366.59% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -89.387% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -19236.495% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 92.783% |
| CorMedix Inc. | 11.91 Million USD | -1043.853% |
| BioLineRx Ltd. | 50.7 Million USD | -168.863% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 8.792% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -54.136% |
| Atai Life Sciences N.V. | 49.16 Million USD | -177.285% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -337.589% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -658.93% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -9.374% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2311.019% |
| MediciNova, Inc. | 3.89 Million USD | -3402.946% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -645.768% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -8962.311% |
| GeoVax Labs, Inc. | 3.51 Million USD | -3772.83% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 65.685% |
| Biomea Fusion, Inc. | 30.69 Million USD | -344.181% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 94.991% |
| Mereo BioPharma Group plc | 15.96 Million USD | -754.022% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -336.906% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -132.293% |
| Absci Corporation | 58.3 Million USD | -133.807% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -615.66% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -325.173% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -84.739% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -55.823% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -303.669% |
| Allakos Inc. | 74.79 Million USD | -82.262% |
| Imunon, Inc. | 8.53 Million USD | -1498.033% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -505.835% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -18.732% |
| BioAtla, Inc. | 48.98 Million USD | -178.282% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1176.371% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -4805.326% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -4.376% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -858.98% |
| XOMA Corporation | 145.58 Million USD | 6.361% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -304.928% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -98.256% |
| aTyr Pharma, Inc. | 31.59 Million USD | -331.43% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -120.499% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -203.167% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -181.639% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -4649.791% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1570.982% |
| Akari Therapeutics, Plc | 4.58 Million USD | -2873.8% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -668.725% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 91.736% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -33650.012% |
| UroGen Pharma Ltd. | 243.52 Million USD | 44.022% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 57.545% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -4836.308% |
| Orgenesis Inc. | 35.53 Million USD | -283.619% |
| Entera Bio Ltd. | 1.37 Million USD | -9785.352% |
| GH Research PLC | 6.7 Million USD | -1934.308% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -1904.691% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -624.1% |
| Xencor, Inc. | 283.55 Million USD | 51.926% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -4465.768% |
| Replimune Group, Inc. | 113.21 Million USD | -20.408% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -3528.28% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -31.671% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -33650.012% |
| Portage Biotech Inc. | 4.45 Million USD | -2963.348% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -8962.311% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -491.406% |
| OncoCyte Corporation | 49.29 Million USD | -176.52% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -3195.273% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -16993.634% |
| Purple Biotech Ltd. | 10 Million USD | -1262.509% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2256.015% |
| scPharmaceuticals Inc. | 57.26 Million USD | -138.066% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1000.41% |
| HilleVax, Inc. | 78.9 Million USD | -72.755% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -2599.386% |
| Tharimmune, Inc. | 1.81 Million USD | -7410.498% |
| Genprex, Inc. | 3.25 Million USD | -4089.007% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -402.67% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -2503.495% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -66074.272% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -37919.735% |
| OKYO Pharma Limited | 7.42 Million USD | -1736.974% |
| Savara Inc. | 37.19 Million USD | -266.528% |
| Curis, Inc. | 57.61 Million USD | -136.616% |
| Daré Bioscience, Inc. | 26.32 Million USD | -417.735% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -247.754% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -9340.374% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -554.782% |
| BeiGene, Ltd. | 2.23 Billion USD | 93.897% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -540.302% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 48.049% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -540.777% |
| Erasca, Inc. | 78.61 Million USD | -73.41% |
| bluebird bio, Inc. | 424.62 Million USD | 67.897% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -20704.057% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 92.788% |
| DBV Technologies S.A. | 42.8 Million USD | -218.502% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -20704.057% |
| Moderna, Inc. | 4.57 Billion USD | 97.018% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1848.806% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -8131.824% |
| Molecular Templates, Inc. | 31.17 Million USD | -337.326% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -698.588% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 76.821% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -9.489% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -396.844% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -273.927% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -145.024% |
| MacroGenics, Inc. | 154.2 Million USD | 11.6% |
| RenovoRx, Inc. | 4.46 Million USD | -2952.373% |
| Adicet Bio, Inc. | 37.12 Million USD | -267.239% |
| Prime Medicine, Inc. | 60.78 Million USD | -124.283% |
| Aditxt, Inc. | 28.53 Million USD | -377.783% |
| Adagene Inc. | 45.16 Million USD | -201.795% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -75338.985% |
| Quantum-Si incorporated | 26.63 Million USD | -411.881% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 80.458% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -4380.584% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -18.578% |
| SciSparc Ltd. | 1.59 Million USD | -8446.646% |
| Vericel Corporation | 127.7 Million USD | -6.745% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2349.624% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -59.702% |
| Generation Bio Co. | 171.63 Million USD | 20.574% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1080.251% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -225.88% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 46.055% |
| Invivyd, Inc. | 51.71 Million USD | -163.607% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -48.21% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -1995.523% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -80.565% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -13251.518% |
| 2seventy bio, Inc. | 310.12 Million USD | 56.044% |
| ADMA Biologics, Inc. | 193.97 Million USD | 29.724% |
| Clene Inc. | 38.95 Million USD | -249.976% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -277.272% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 46.953% |
| GeoVax Labs, Inc. | 3.51 Million USD | -3772.83% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 28.352% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1019.235% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 31.264% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1017.845% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -183.343% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -157.98% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 63.142% |
| Evaxion Biotech A/S | 17.61 Million USD | -673.771% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 15.292% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 11.011% |
| Trevena, Inc. | 48.26 Million USD | -182.456% |
| Surrozen, Inc. | 8.14 Million USD | -1573.653% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -531.253% |
| Cingulate Inc. | 10.36 Million USD | -1215.711% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -4857.055% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -265.545% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -3700.871% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -936.646% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 57.024% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -448.589% |
| Clearmind Medicine Inc. | 3.61 Million USD | -3676.141% |
| Kronos Bio, Inc. | 54.2 Million USD | -151.506% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -189.775% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -498.948% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -579.184% |
| Statera Biopharma, Inc. | 22.67 Million USD | -501.148% |
| ImmunityBio, Inc. | 1.09 Billion USD | 87.498% |
| Korro Bio, Inc. | 51.75 Million USD | -163.408% |
| Kineta, Inc. | 7.22 Million USD | -1787.552% |
| BioVie Inc. | 9.7 Million USD | -1305.042% |
| Codexis, Inc. | 49.94 Million USD | -172.933% |
| Celularity Inc. | 102.92 Million USD | -32.44% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -41.635% |
| Celcuity Inc. | 51.45 Million USD | -164.954% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -39390.547% |
| Cibus, Inc. | 206.11 Million USD | 33.863% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -220.939% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -417.556% |
| IN8bio, Inc. | 8.77 Million USD | -1454.024% |
| Kodiak Sciences Inc. | 213.59 Million USD | 36.178% |
| Annexon, Inc. | 47.11 Million USD | -189.314% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -52.242% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -41.451% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -895.829% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 94.764% |
| Eyenovia, Inc. | 19.78 Million USD | -589.166% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 23.021% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1674.756% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -465.662% |
| Arcellx, Inc. | 339.75 Million USD | 59.877% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1045.73% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 44.482% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1325.484% |
| Moolec Science SA | 13.94 Million USD | -877.523% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -215.904% |
| Geron Corporation | 146.12 Million USD | 6.712% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -169.768% |
| Royalty Pharma plc | 6.29 Billion USD | 97.835% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -242.717% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -46203.064% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -5440.788% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 27.933% |
| Humacyte, Inc. | 114.67 Million USD | -18.872% |
| Structure Therapeutics Inc. | 29.05 Million USD | -369.24% |
| 89bio, Inc. | 59.96 Million USD | -127.339% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -415.131% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -11297.91% |
| Genelux Corporation | 8.42 Million USD | -1518.99% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -1888.317% |
| Notable Labs, Ltd. | 4.42 Million USD | -2979.264% |
| Liquidia Corporation | 73.13 Million USD | -86.386% |
| Mustang Bio, Inc. | 17.61 Million USD | -673.705% |
| Immunovant, Inc. | 48.95 Million USD | -178.458% |
| Quantum-Si incorporated | 26.63 Million USD | -411.881% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -255.155% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -4293.136% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -84.562% |
| Acasti Pharma Inc. | 11.55 Million USD | -1079.536% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -502.975% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -4914.667% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -269.659% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -9902.553% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -2136.204% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -448.899% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -487.987% |
| PepGen Inc. | 34.63 Million USD | -293.633% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1022.521% |
| United Therapeutics Corporation | 1.18 Billion USD | 88.469% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1851.876% |
| Solid Biosciences Inc. | 38.45 Million USD | -254.462% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1493.034% |
| Immuneering Corporation | 12 Million USD | -1035.201% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -43333.336% |
| Silo Pharma, Inc. | 1.56 Million USD | -8586.778% |
| Belite Bio, Inc | 4.21 Million USD | -3137.212% |
| XOMA Corporation | 145.58 Million USD | 6.361% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -5514.456% |
| Bionomics Limited | 10.15 Million USD | -1241.891% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -534.307% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -494.942% |
| uniQure N.V. | 624.01 Million USD | 78.155% |
| Cassava Sciences, Inc. | 14.19 Million USD | -860.331% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -75338.985% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 19.899% |
| Forte Biosciences, Inc. | 3.66 Million USD | -3618.467% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -52213.083% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -1920.439% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1674.756% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -684.209% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1189.922% |
| Altimmune, Inc. | 16.54 Million USD | -724.128% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 77.931% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -494.942% |
| Compugen Ltd. | 55.77 Million USD | -144.409% |
| Peak Bio, Inc. | 20.75 Million USD | -556.853% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -23.407% |
| Benitec Biopharma Inc. | 4.96 Million USD | -2647.259% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 13.636% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -81.338% |
| Zura Bio Limited | 21.29 Million USD | -540.236% |
| PolyPid Ltd. | 17.46 Million USD | -680.393% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -21.281% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -81.338% |
| Instil Bio, Inc. | 99.8 Million USD | -36.591% |
| argenx SE | 444.95 Million USD | 69.363% |
| Immunome, Inc. | 28.65 Million USD | -375.675% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1535.109% |
| Verona Pharma plc | 58.84 Million USD | -131.673% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -841.885% |
| Shattuck Labs, Inc. | 14.85 Million USD | -817.417% |
| CervoMed Inc. | 2.59 Million USD | -5151.629% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -2696.861% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -970.344% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1193.963% |
| Moolec Science SA | 13.94 Million USD | -877.523% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -5716.888% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -145.199% |
| AnaptysBio, Inc. | 364.28 Million USD | 62.579% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1040.172% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -974.732% |
| NeurAxis, Inc. | 1.91 Million USD | -7026.9% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -250.182% |
| Lumos Pharma, Inc. | 13.33 Million USD | -922.418% |
| Achilles Therapeutics plc | 19.08 Million USD | -614.198% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -841.885% |
| 180 Life Sciences Corp. | 5.38 Million USD | -2430.42% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -477.917% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -498.948% |
| Nutriband Inc. | 1.07 Million USD | -12534.776% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -345.516% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -839.418% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 66.028% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -319.792% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -944.662% |
| Palisade Bio, Inc. | 2.73 Million USD | -4876.962% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -2495.069% |
| Beam Therapeutics Inc. | 478.38 Million USD | 71.504% |
| Neurogene Inc. | 36.54 Million USD | -272.976% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 65.745% |
| AEON Biopharma, Inc. | 159.88 Million USD | 14.741% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -186.084% |
| Sesen Bio, Inc. | 30.98 Million USD | -339.966% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -425.091% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -1693.148% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 30.356% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 29.022% |
| Athira Pharma, Inc. | 30.05 Million USD | -353.535% |
| Vaccinex, Inc. | 5.94 Million USD | -2194.16% |
| HCW Biologics Inc. | 15.05 Million USD | -805.657% |
| XOMA Corporation | 145.58 Million USD | 6.361% |
| Nektar Therapeutics | 267.04 Million USD | 48.953% |
| Arvinas, Inc. | 644.6 Million USD | 78.852% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -668.725% |
| Merus N.V. | 102.15 Million USD | -33.449% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 6.854% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -43.313% |
| Rezolute, Inc. | 11.73 Million USD | -1061.744% |
| Clene Inc. | 38.95 Million USD | -249.976% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -4687.524% |
| BeyondSpring Inc. | 48.26 Million USD | -182.415% |
| Synlogic, Inc. | 32.89 Million USD | -314.406% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -832.861% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -8242.656% |
| Peak Bio, Inc. | 20.75 Million USD | -556.853% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -114.814% |
| Krystal Biotech, Inc. | 39.71 Million USD | -243.252% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 63.807% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -36.909% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -31402.383% |
| MannKind Corporation | 721.36 Million USD | 81.103% |
| Ikena Oncology, Inc. | 22.33 Million USD | -510.338% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -6434.947% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -32.877% |
| Gossamer Bio, Inc. | 249.14 Million USD | 45.286% |
| CohBar, Inc. | 1.03 Million USD | -13088.273% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1175.32% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -615.66% |
| Legend Biotech Corporation | 589.93 Million USD | 76.892% |
| Mural Oncology plc | 37.92 Million USD | -259.415% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -2.777% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -5838.967% |
| Disc Medicine, Inc. | 22.87 Million USD | -495.93% |
| Champions Oncology, Inc. | 28.03 Million USD | -386.246% |
| REGENXBIO Inc. | 262.22 Million USD | 48.015% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -3957.896% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -987.594% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -914.911% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -542.863% |
| Vaxart, Inc. | 34.02 Million USD | -300.644% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -568.582% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -377.778% |
| Cellectis S.A. | 249.57 Million USD | 45.38% |
| Longeveron Inc. | 5.33 Million USD | -2454.225% |
| Repare Therapeutics Inc. | 41.81 Million USD | -225.974% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 94.332% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -125.813% |
| Revolution Medicines, Inc. | 262.39 Million USD | 48.049% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -6369.815% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1480.327% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1055.148% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -870.726% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -6237.471% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.353% |
| Denali Therapeutics Inc. | 122.96 Million USD | -10.862% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2349.624% |
| Veru Inc. | 32.81 Million USD | -315.446% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -1884.554% |
| Cingulate Inc. | 10.36 Million USD | -1215.711% |
| Passage Bio, Inc. | 39.26 Million USD | -247.203% |
| Context Therapeutics Inc. | 4.19 Million USD | -3152.106% |
| Exicure, Inc. | 8.54 Million USD | -1494.561% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -361.973% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1200.01% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -518.479% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 16.362% |
| Nuvalent, Inc. | 31.82 Million USD | -328.366% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -2042.832% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -116.304% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -657.328% |
| OmniAb, Inc. | 87.4 Million USD | -55.971% |
| Anew Medical, Inc. | 8.24 Million USD | -1553.996% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -256.026% |
| Lipocine Inc. | 2.63 Million USD | -5080.023% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -418.876% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -239.001% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -411.673% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -58.227% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -2423.959% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -64.742% |
| Ocugen, Inc. | 23.98 Million USD | -468.398% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -193.747% |
| Q32 Bio Inc. | 233.12 Million USD | 41.526% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1403.629% |
| Alumis Inc. Common Stock | 53.5 Million USD | -154.792% |
| Equillium, Inc. | 27.95 Million USD | -387.602% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 34.015% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2322.732% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -2122.725% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 13.353% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -96.332% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1266.716% |
| Dominari Holdings Inc. | 4.63 Million USD | -2841.079% |
| Edesa Biotech, Inc. | 1.84 Million USD | -7302.056% |
| vTv Therapeutics Inc. | 29.56 Million USD | -361.051% |
| Bio-Techne Corporation | 744.34 Million USD | 81.686% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -8.105% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 60.425% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -235.968% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -370.764% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -47.595% |
| Nkarta, Inc. | 105.6 Million USD | -29.09% |
| BioCardia, Inc. | 4.59 Million USD | -2869.913% |
| Iterum Therapeutics plc | 32.66 Million USD | -317.363% |